GrayBug
Signal active
Organization
Contact Information
Overview
GrayBug is a pharmaceutical company that develops transformative medicines for ocular diseases. They also develop therapies for inflammatory diseases with unmet needs. Their proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury.
About
Industries
Biotechnology, Health Care, Pharmaceutical, Medical
Founded
2011
Employees
1-10
Headquarters locations
United States, North America
Social
N/A
Profile Resume
GrayBug headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Medical sector. The company focuses on Biotechnology and has secured $12.4B in funding across 96 round(s). With a team of 1-10 employees, GrayBug is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - GrayBug, raised $1.5M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
6
Investors
2
Lead Investors
0
Total Funding Amount
$129.2M
Details
4
GrayBug has raised a total of $129.2M in funding over 4 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2019 | Late Stage Venture | 80.0M | ||
| 2016 | Early Stage Venture | 44.5M | ||
| 2015 | Early Stage Venture | 1.7M | ||
| 2013 | Early Stage Venture | 1.5M |
Investors
GrayBug is funded by 21 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| GrayBug | - | FUNDING ROUND - GrayBug | 1.7M |
| Maryland Venture Fund | - | FUNDING ROUND - Maryland Venture Fund | 1.7M |
| GrayBug | - | FUNDING ROUND - GrayBug | 1.5M |
| Frank A. Bonsal | - | FUNDING ROUND - Frank A. Bonsal | 1.5M |
Recent Activity
There is no recent news or activity for this profile.